Positive Allosteric Modulators Segmentation
The market is segmented by disease type into Parkinson’s disease, schizophrenia, Alzheimer’s disease, and others out of which, the Alzheimer’s disease segment is anticipated to hold a substantial share in the global positive allosteric modulators market over the forecast period on account of high prevalence of the disorder across the globe. Meanwhile, the Parkinson’s disease segment is also estimated to hold a notable size in the market during the forecast period, owing to the ongoing growth in the cases of the disease. According to the statistics by the Parkinson’s Foundation, more than 10 million people are living with this disorder globally.
Our in-depth analysis of the global positive allosteric modulators market includes the following segments:
|
By Disease Type |
|
|
By Drug Type |
|
|
By End User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Positive Allosteric Modulators Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
The increasing prevalence of Parkinson’s disease, schizophrenia, Alzheimer’s disease, and other mental disorder will boost the market growth.
Asia Pacific industry is likely to hold largest revenue share by 2037, on account of increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.
The major players in the market are Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, and Pfizer Inc.
